MEDI-0457 is under clinical development by AstraZeneca and currently in Phase II for Glioblastoma Multiforme (GBM). According to GlobalData, Phase II drugs for Glioblastoma Multiforme (GBM) have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MEDI-0457’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MEDI-0457 overview
MEDI-0457 (VGX-3100 plus DNA-based IL-12 cytokine) is under development for the treatment of cervical cancer, vulvar cancer, anal, penile cancer and vaginal cancer, newly diagnosed glioblastoma, HPV-caused head and neck squamous cell carcinoma (HNSCC). It is administered intramuscularly by electroporation. INO-3112 is DNA-based combination immunotherapeutic composed of VGX-3100 DNA plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18 combined with INO-9012, a DNA plasmid encoding interleukin-12 (IL-12). The vaccine is developed based on SynCon DNA vaccine technology, ASPIRE technology and CELLECTRA electroporation-based delivery technology. It was also under development for , HPV positive oropharyngeal squamous cell carcinoma, advanced unresectable or metastatic urothelial carcinoma.
See Also:
AstraZeneca overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly- owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of MEDI-0457’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
